Full Press Release Details
ChromaDex Appoints Kurt Gustafson to its Board of
IRVINE, Calif., Oct. 27, 2016
ChromaDex Corp. (NASDAQ: CDXC), an
innovator of proprietary health, wellness and nutritional
ingredients that creates science-based solutions for dietary
supplement, food and beverage, skin care, sports nutrition, and
pharmaceutical products, announced today that Kurt Gustafson has
joined the Company's board of directors. Mr. Gustafson will
also serve as chair of ChromaDex's audit
Gustafson, age 48, has more than 25 years of diverse experience in
corporate finance. He currently serves as chief financial officer,
principal accounting officer and executive vice president of
Spectrum Pharmaceuticals, Inc. He previously served as the chief
financial officer of Halozyme Therapeutics, Inc. (2009
2013). From 1991 to 2009 he worked at Amgen, holding various
financial roles as vice president finance, chief financial officer
of Amgen International and treasurer. Prior to joining Amgen, he
worked in public accounting as staff auditor at Laventhol &
Horwath in Chicago. He has been an independent director of Xencor,
Inc. since 2014. Mr. Gustafson holds a B.A. degree in Accounting
from North Park University in Chicago and an M.B.A from University
of California, Los Angeles.
ChromaDex leverages its complementary business
units to discover, acquire, develop and commercialize patented and
proprietary ingredient technologies that address the dietary
supplement, food, beverage, skin care and pharmaceutical markets.
In addition to our ingredient technologies unit, we also have
business units focused on natural product fine chemicals (known as
"phytochemicals"), chemistry and analytical testing services, and
product regulatory and safety consulting (known as Spherix
Consulting). As a result of our relationships with leading
universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then
utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our
ingredient portfolio is backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of
patented ingredient technologies includes
nicotinamide riboside;
pterostilbene; PURENERGY ,
a caffeine-pTeroPure co-crystal; IMMULINA , a spirulina extract; and
AnthOrigin , anthocyanins derived from a
domestically-produced, water-extracted purple corn. To learn more
about ChromaDex, please visit www.ChromaDex.com.
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended January 2, 2016, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date
Public Relations Contact:
Ostendorf, Director of Marketing
Investor Relations Contact:
Johnson, Director of Investor Relations